Codexis develops enzymatic solutions for pharmaceutical manufacturing, with a focus on therapeutics production. The company operates through its CodeEvolver technology platform, which enables the discovery, development, and optimization of novel enzymes. A primary application is the ECO Synthesis manufacturing platform, designed to facilitate scaled production of RNAi therapeutics using enzymatic routes rather than conventional chemical synthesis methods.
The company generates revenue through licensing agreements and collaborative partnerships with pharmaceutical manufacturers. Notable collaborations include arrangements with Aldevron LLC and Pfizer Inc. for the application of Codexis's enzymatic technologies in therapeutic manufacturing processes.
With 188 full-time employees, Codexis maintains headquarters in Redwood City, California. The company operates internationally across North America, Latin America, Europe, the Middle East, Africa, Asia-Pacific regions including Australia, New Zealand, and Southeast Asia, and China. Codexis was incorporated in Delaware in 2002 and trades on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.89 | $-0.89 | +20.5% | |
| 2023 | $-1.12 | $-1.12 | -119.6% | |
| 2022 | $-0.51 | $-0.51 | -54.5% | |
| 2021 | $-0.33 | $-0.33 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-02-27 | 0001200375-25-000003 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0001200375-24-000009 | SEC ↗ |
| 2022-12-31 | 2023-02-27 | 0001200375-23-000012 | SEC ↗ |
| 2021-12-31 | 2022-02-28 | 0001200375-22-000010 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001200375-21-000021 | SEC ↗ |
| 2019-12-31 | 2020-02-28 | 0001200375-20-000008 | SEC ↗ |
| 2018-12-31 | 2019-03-01 | 0001200375-19-000005 | SEC ↗ |
| 2017-12-31 | 2018-03-15 | 0001200375-18-000009 | SEC ↗ |
| 2016-12-31 | 2017-03-09 | 0001200375-17-000007 | SEC ↗ |
| 2015-12-31 | 2016-03-08 | 0001200375-16-000052 | SEC ↗ |
| 2014-12-31 | 2015-03-06 | 0001200375-15-000008 | SEC ↗ |
| 2013-12-31 | 2014-03-13 | 0001200375-14-000011 | SEC ↗ |
| 2012-12-31 | 2013-04-02 | 0001445305-13-000770 | SEC ↗ |
| 2011-12-31 | 2012-03-05 | 0001193125-12-096779 | SEC ↗ |
| 2010-12-31 | 2011-02-10 | 0001193125-11-030827 | SEC ↗ |